Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Income from Continuing Operations (2019 - 2025)

Silo Pharma's Income from Continuing Operations history spans 7 years, with the latest figure at 1110438.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 19.55% year-over-year to 1110438.0; the TTM value through Sep 2025 reached 5076788.0, down 36.7%, while the annual FY2024 figure was 4392880.0, 20.98% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 1110438.0 at Silo Pharma, up from 1204293.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 6472438.0 in Q3 2021 and bottomed at 1812792.0 in Q1 2023.
  • The 5-year median for Income from Continuing Operations is 1012951.0 (2023), against an average of 664721.89.
  • The largest YoY upside for Income from Continuing Operations was 1121.22% in 2021 against a maximum downside of 261.66% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 1062788.0 in 2021, then plummeted by 56.46% to 1662831.0 in 2022, then skyrocketed by 36.76% to 1051576.0 in 2023, then crashed by 64.57% to 1730620.0 in 2024, then skyrocketed by 35.84% to 1110438.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Income from Continuing Operations are 1110438.0 (Q3 2025), 1204293.0 (Q2 2025), and 1031437.0 (Q1 2025).